{"id":749106,"date":"2023-04-19T09:24:19","date_gmt":"2023-04-19T13:24:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/"},"modified":"2023-04-19T09:24:19","modified_gmt":"2023-04-19T13:24:19","slug":"silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/","title":{"rendered":"Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders"},"content":{"rendered":"<h2>\nData to Support Alzheimer\u2019s Study<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">ENGLEWOOD CLIFFS, NJ, April  19, 2023  (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. \u00a0(Nasdaq:SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has commenced development of a novel formulation as a targeted prophylactic treatment, designated as SPC-15, intended for stress, anxiety, and PTSD.<\/p>\n<p>Development of the drug formulation is pursuant to the Company\u2019s sponsored research agreement with Columbia University. Preclinical studies in the field suggest that SPC-15 could be a promising therapeutic target for the treatment of cognitive impairment, PTSD, and stress-related disorders.<\/p>\n<p>\u201cWe are advancing our development of SPC-15 through this formulation and feasibility study investigating dose strengths and delivery,\u201d said Eric Weisblum, Chief Executive Officer of Silo Pharma.\u00a0\u201cThe SPC-15 treatment protocol predicts levels of severity or progression of stress-related disorders and their metabolomic biomarkers\u2019 response to pharmacological treatments. Based on our own research to date coupled with published preclinical data, we believe SPC-15 could have a profound impact on treating stress and anxiety disorders including PTSD, we will further use this data to help us with our upcoming studies related to SPC-14 Alzheimer\u2019s asset.\u201d\u00a0<\/p>\n<p>Targeted by SPC-15, anxiety, PTSD, and other stress-related disorders are becoming more frequent in Americans aged 18+. According to the World Health Organization in 2019, 300+ million people were living with an anxiety disorder, and according to the National Center for PTSD, around 12 million adults in the U.S. alone are reported to have PTSD.<sup>,<\/sup> According to Fortune Business Insights, the global treatment market size for anxiety disorders and depression is projected to reach $13.0 billion in 2027.<\/p>\n<p>Silo Pharma was recently granted a <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RmlqlgFROOYHaDf9JZIThF2pkSMIX7m05LjKg_LwumbtpCbhbgaG5cylavsXw_g4WWSctd59nf1iDQsJfN6mWbe_TFaLYgPV7rvt2czsYOSiOK8jQd1nS_ykJToxZCp_MihVD0OhiMa9o39QhVLyOHcEFHxb_IUJT54n7zb9Hpb-hn7pRva9LTW696DpMA0PEA5CAmysUuqVI6ZFAw301uRdcB5lOzRx5Nzpxn0Wb78=\" rel=\"nofollow noopener\" target=\"_blank\"><u>U.S. patent<\/u><\/a> covering SPC-15 as a method for the treatment and prevention of stress-induced affective disorders in females.<\/p>\n<p>\n        <strong>About Silo Pharma\u00a0<\/strong>\n      <\/p>\n<p>Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer\u2019s disease, and other rare neurological disorders. Silo\u2019s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NOA_D9dkQZLTgHW7hQ8NIi_ugrJLCQ63J-Yf4WfYvNmFZf2PShajqm85F39r7sl1nlUeDAl9hOegQGmY1hmq9tlC7ZTjkTyYAHuwJEBwzi8=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.silopharma.com<\/u><\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements\u00a0<\/strong>\n      <\/p>\n<p>All statements other than statements of historical fact in this announcement are forward-looking statements that involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;is\/are likely to&#8221; or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company&#8217;s filings with the SEC.<\/p>\n<p>\n        <strong>Contact\u00a0<\/strong><br \/>\n        <br \/>800-705-0120\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nkqSN6YZTKAV1A2swQv1DYGNDBF99ophzOQykGnu5MxipUhX9L3jXp2azbuWujlYPYhdlYFlEC9EOn46D7Fa50QwhpTIdfePlLIpkLif5qA=\" rel=\"nofollow noopener\" target=\"_blank\"><u>investors@silopharma.com<\/u><\/a><\/p>\n<p>World Health Organization; Mental disorders. June 2022.<br \/>U.S. Department of Veterans Affairs, PTSD: National Center for PTSD; How Common Is PTSD in Adults?<\/p>\n<p>\n        \n      <\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDgwMiM1NTM0Mzc1IzUwMDA2OTMzOQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OWNiYThlZTYtZTgyMy00YWFiLWFiNTAtZjZjZGE2OGIzYzkxLTUwMDA2OTMzOQ==\/tiny\/Silo-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Data to Support Alzheimer\u2019s Study ENGLEWOOD CLIFFS, NJ, April 19, 2023 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. \u00a0(Nasdaq:SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has commenced development of a novel formulation as a targeted prophylactic treatment, designated as SPC-15, intended for stress, anxiety, and PTSD. Development of the drug formulation is pursuant to the Company\u2019s sponsored research agreement with Columbia University. Preclinical studies in the field suggest that SPC-15 could be a promising therapeutic target for the treatment of cognitive impairment, PTSD, and stress-related disorders. \u201cWe are advancing our development of SPC-15 through this formulation and feasibility study investigating dose strengths and delivery,\u201d said Eric Weisblum, Chief &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-749106","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data to Support Alzheimer\u2019s Study ENGLEWOOD CLIFFS, NJ, April 19, 2023 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. \u00a0(Nasdaq:SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has commenced development of a novel formulation as a targeted prophylactic treatment, designated as SPC-15, intended for stress, anxiety, and PTSD. Development of the drug formulation is pursuant to the Company\u2019s sponsored research agreement with Columbia University. Preclinical studies in the field suggest that SPC-15 could be a promising therapeutic target for the treatment of cognitive impairment, PTSD, and stress-related disorders. \u201cWe are advancing our development of SPC-15 through this formulation and feasibility study investigating dose strengths and delivery,\u201d said Eric Weisblum, Chief &hellip; Continue reading &quot;Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-19T13:24:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDgwMiM1NTM0Mzc1IzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders\",\"datePublished\":\"2023-04-19T13:24:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\\\/\"},\"wordCount\":579,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMDgwMiM1NTM0Mzc1IzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\\\/\",\"name\":\"Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMDgwMiM1NTM0Mzc1IzUwMDA2OTMzOQ==\",\"datePublished\":\"2023-04-19T13:24:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMDgwMiM1NTM0Mzc1IzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgxMDgwMiM1NTM0Mzc1IzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders - Market Newsdesk","og_description":"Data to Support Alzheimer\u2019s Study ENGLEWOOD CLIFFS, NJ, April 19, 2023 (GLOBE NEWSWIRE) &#8212; Silo Pharma, Inc. \u00a0(Nasdaq:SILO) (\u201cthe Company\u201d), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has commenced development of a novel formulation as a targeted prophylactic treatment, designated as SPC-15, intended for stress, anxiety, and PTSD. Development of the drug formulation is pursuant to the Company\u2019s sponsored research agreement with Columbia University. Preclinical studies in the field suggest that SPC-15 could be a promising therapeutic target for the treatment of cognitive impairment, PTSD, and stress-related disorders. \u201cWe are advancing our development of SPC-15 through this formulation and feasibility study investigating dose strengths and delivery,\u201d said Eric Weisblum, Chief &hellip; Continue reading \"Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-19T13:24:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDgwMiM1NTM0Mzc1IzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders","datePublished":"2023-04-19T13:24:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/"},"wordCount":579,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDgwMiM1NTM0Mzc1IzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/","name":"Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDgwMiM1NTM0Mzc1IzUwMDA2OTMzOQ==","datePublished":"2023-04-19T13:24:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDgwMiM1NTM0Mzc1IzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgxMDgwMiM1NTM0Mzc1IzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-commences-formulation-for-spc-15-targeting-anxiety-and-ptsd-stress-related-disorders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=749106"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/749106\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=749106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=749106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=749106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}